{"id":20240,"date":"2026-11-19T05:15:29","date_gmt":"2026-11-19T08:15:29","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1795076128886\/"},"modified":"2026-11-19T05:15:36","modified_gmt":"2026-11-19T08:15:36","slug":"dbt-high-risk-breast-lesions","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/dbt-high-risk-breast-lesions\/","title":{"rendered":"DBT finds more high-risk benign breast lesions"},"content":{"rendered":"<p>Digital breast tomosynthesis (DBT) detects more high-risk benign breast disease than 2D digital mammography, especially radial sclerosing lesions, according to an analysis of 4.47 million screening mammograms in the U.S. Breast Cancer Surveillance Consortium (BCSC). The study, led by Brian L. Sprague, PhD, of the University of Vermont Department of Surgery, was published November 17 in <em>Radiology<\/em> alongside an editorial on whether that extra detection should mean extra surgery.<\/p>\n<p>With DBT, the adjusted odds that a screening exam ended in a high-risk benign diagnosis were 36% higher than with digital mammography. For radial sclerosing lesions, the odds ratio reached 2.64.<\/p>\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" class=\"alignright lazyload\" data-src=\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/11\/dbt-high-risk-benign-breast-disease.png\" alt=\"Odds ratio chart: tomosynthesis detects more high-risk benign breast disease than digital mammography, with the largest effect for radial sclerosing lesions (2.64)\" width=\"640\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1200px; --smush-placeholder-aspect-ratio: 1200\/630;\"><figcaption>Adjusted odds ratios (95% CI) for detection with DBT vs. digital mammography. RT Medical chart based on Sprague BL et al., Radiology, 2026.<\/figcaption><\/figure>\n<h2>What the BCSC study measured over nearly two decades<\/h2>\n<p>This was a retrospective cohort study using prospectively collected data from the BCSC, a network of U.S. screening mammography registries. It included screening exams performed from 2005 to 2022 in women aged 40 to 79 at 97 facilities; exams in women with prior breast cancer or mastectomy were excluded. The final sample was 4,469,664 exams in 1,190,380 women, with a mean age of 57.3 years. According to Diagnostic Imaging&#8217;s account of the full text, 58.3% of exams were digital mammography, 25.5% DBT and 15.8% film.<\/p>\n<p>The investigators used regression models to estimate the annual percent change (APC) in detection rates and multivariable logistic regression to compare modalities. The overall high-risk benign breast disease (BBD) detection rate was 1.11 per 1,000 exams, or roughly one diagnosis for every 900 screening mammograms. Since 2017 there was no evidence of a trend for the group as a whole (APC 5.3%; 95% CI \u22121.1 to 21.9; p = 0.09).<\/p>\n<p>Individual diagnoses moved in opposite directions. Detection of atypical ductal hyperplasia (ADH) fell from 2009 to 2017 (APC \u22127.4%; p &lt; 0.001); Diagnostic Imaging adds that it had been rising 9.4% a year over the preceding four years, a figure not stated in the abstract. Radial sclerosing lesions (APC 5.4%) and atypical papillary lesions (APC 19.0%) rose from 2005 to 2022, both with p &lt; 0.001.<\/p>\n<p>Head to head, DBT had adjusted odds ratios of 1.36 for high-risk BBD overall (95% CI 1.24 to 1.49), 1.37 for lobular carcinoma in situ (1.02 to 1.85; p = 0.04), 1.45 for atypical lobular hyperplasia (1.19 to 1.77) and 2.64 for radial sclerosing lesions (2.15 to 3.23). Because the outcome is rare, the odds ratio approximates the relative risk, which is why both outlets could describe it as &#8220;36% higher detection.&#8221; The abstract does not list ADH among the diagnoses with higher detection on DBT.<\/p>\n<h2>What counts as high-risk benign breast disease<\/h2>\n<p>The category covers histologic findings that are not cancer but are linked to a higher future risk of breast cancer: ADH, atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS, which despite its name is managed in its classic form as a risk marker), radial sclerosing lesions (radial scar and complex sclerosing lesion) and papillary lesions with atypia. The authors stress that there is no clear evidence to define these diagnoses as obligate cancer precursors.<\/p>\n<p>The clinical dilemma starts when one of them shows up on a percutaneous biopsy, because surgery may find in situ or invasive cancer the needle missed, the so-called upgrade. For years, surgical excision was the default. ADH generally still follows that path because it carries the highest underestimation rates.<\/p>\n<h2>Why architectural distortion matters so much on DBT<\/h2>\n<p>DBT acquires several low-dose projections over an arc and reconstructs the breast in thin slices, which reduces tissue overlap. The sign that benefits most is architectural distortion: spiculations converging on a point without a clear central mass, often invisible on 2D mammography or mistaken for summation. It is the classic appearance of a radial scar.<\/p>\n<p>The authors wrote that the rise in radial sclerosing lesions &#8220;is likely due to the improved visualization of architectural distortion, which is a hallmark of radial sclerosing lesions,&#8221; while noting that changes in how pathologists make the diagnosis may also have contributed. In practice, distortions seen only on DBT often have no sonographic correlate and end up in DBT-guided biopsy. The debate over <a href=\"https:\/\/rtmedical.com.br\/en\/ultrasound-screening-dbt-era\/\">screening ultrasound in the DBT era<\/a> and the <a href=\"https:\/\/rtmedical.com.br\/en\/handheld-breast-us-blind-spots\/\">blind spots of handheld breast ultrasound<\/a> help explain why a targeted scan does not always settle these cases.<\/p>\n<h2>More diagnoses need not mean more surgery<\/h2>\n<p>In the accompanying editorial, Regina Hooley, MD, professor of radiology and biomedical imaging at the Yale School of Medicine, takes on the overtreatment argument: &#8220;Critics may argue that finding additional high-risk BBD requiring excision will lead to more unnecessary surgeries. However, while breast cancer screening has evolved, so has histologic diagnosis and management of high-risk BBD.&#8221; She notes that management of radial sclerosing lesions, and of radiology-pathology concordant LCIS and ALH, has de-escalated, so many women are now followed with imaging rather than operated on.<\/p>\n<p>The authors call for studies that pin down upgrade rates at surgical excision and test the effectiveness of active surveillance and risk-reducing strategies. That fits a broader push toward less invasive breast care, also visible in the case for <a href=\"https:\/\/rtmedical.com.br\/en\/breast-cryoablation-pays-its-way\/\">breast cryoablation in outpatient practice<\/a>.<\/p>\n<h2>Practical steps for breast imaging services<\/h2>\n<p>For practices moving from 2D mammography to DBT, the editorial takeaway is operational: expect more architectural distortions and more pathology reports of radial scar and lobular lesions. That calls for DBT-guided biopsy capability, a standing radiology-pathology concordance review and a written high-risk lesion protocol that spells out when to recommend surgical excision, vacuum-assisted excision or imaging follow-up. In regions where DBT is still concentrated in private and academic centers, as in much of Latin America, the same planning applies as access expands.<\/p>\n<p>It is also worth auditing the high-risk lesion rate per 1,000 exams alongside cancer detection rate and biopsy positive predictive value; the U.S. figure of 1.11 per 1,000 offers a benchmark for spotting outliers. Reading time, another DBT cost, is the target of tools such as <a href=\"https:\/\/rtmedical.com.br\/en\/ai-slabs-dbt-reading-time\/\">AI-generated slabs to cut DBT reading time<\/a>.<\/p>\n<h2>Limitations: detecting more is not the same as having more<\/h2>\n<p>The authors caution that the temporal trends may not reflect changes in the incidence of these benign diseases, because mammographic modalities, biopsy practices and classification schemes all shifted during the study period. The design is observational: the odds ratios are adjusted, but facilities that adopted DBT may differ in biopsy thresholds, patient mix and pathologists. The cohort is limited to U.S. women aged 40 to 79, and the abstract does not report whether the extra lesions changed cancer outcomes, so benefit cannot be separated from overdiagnosis. The next step is to measure the real upgrade rate of lesions seen only on DBT and to test active surveillance prospectively.<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/www.auntminnie.com\/clinical-news\/womens-imaging\/breast\/article\/16541981\/dbt-tied-to-higher-detection-of-highrisk-benign-breast-disease\" target=\"_blank\" rel=\"noopener\">AuntMinnie \u2014 DBT tied to higher detection of high-risk benign breast disease<\/a>; <a href=\"https:\/\/www.diagnosticimaging.com\/view\/dbt-36-percent-higher-detection-rate-high-risk-benign-breast-disease-digital-mammography\" target=\"_blank\" rel=\"noopener\">Diagnostic Imaging \u2014 DBT Associated with 36 Percent Higher Detection Rate for High-Risk Benign Breast Disease than Digital Mammography<\/a>. Study: <a href=\"https:\/\/doi.org\/10.1148\/radiol.260889\" target=\"_blank\" rel=\"noopener\">Sprague BL et al., Radiology, 2026<\/a>; editorial: <a href=\"https:\/\/doi.org\/10.1148\/radiol.263046\" target=\"_blank\" rel=\"noopener\">Hooley R, Radiology, 2026<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DBT raised the odds of detecting high-risk benign breast disease by 36% in 4.47 million screening exams. See what it means for biopsy.<\/p>\n","protected":false},"author":5,"featured_media":20203,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[100],"tags":[],"class_list":["post-20240","post","type-post","status-publish","format-standard","has-post-thumbnail","category-radiology"],"aioseo_notices":[],"rt_seo":{"title":"","description":"DBT raised the odds of detecting high-risk benign breast disease by 36% in 4.47 million screening exams. See what it means for biopsy.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"DBT and high-risk benign breast disease detection (Radiology, 2026)","llms_summary":"BCSC study of 4,469,664 screening mammograms (2005-2022, 97 U.S. facilities): DBT vs digital mammography adjusted odds ratios were 1.36 for high-risk benign breast disease overall, 1.37 for LCIS, 1.45 for ALH and 2.64 for radial sclerosing lesions; overall rate 1.11 per 1,000 exams. Hooley's editorial highlights de-escalated excision.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20240\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/5\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=20240"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20240\/revisions\/"}],"predecessor-version":[{"id":20244,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20240\/revisions\/20244\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/20203\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=20240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=20240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=20240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}